| [1] PubMed ID: | 35228660 |
| Disease Name: | lung squamous cell carcinoma |
| Sample: | LUSC cells |
| Dysfunction Pattern: | Interaction(E2F7/LINC00649/TAF15/MAPK6/MAPK signaling pathway) |
| Validated Method: | Western Blot//CCK8//qRT-PCR//Flow Cytometry//Luciferase Report Assay//Colony Formation Assay |
| Description: | As a result, LINC00649 was discovered to be with high expression in LUSC cells. Results of mechanism assays validated that E2F transcription factor 7 (E2F7) was a transcription activator of LINC00649 and induced its up-regulation in LUSC cells. Furthermore, LINC00649 recruited TAF15, which is TATA-box binding protein associated factor 15 to stabilize mitogen-activated protein kinase 6 (MAPK6) expression and activate the transcription of MAPK6, thereby enhancing MAPK6 expression to activate the MAPK signaling pathway. In summary, our research determined the E2F7/LINC00649/TAF15/MAPK6/MAPK signaling pathway in regulating LUSC development, which made LINC00649 a potential biomarker for LUSC treatment. |
| Causality: | Yes |
| Causal Description: | Moreover, it was confirmed through functional assays that the knockdown of LINC00649 hindered the occurrence and progression of LUSC. |
| Clinical-realted Application: | |